---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-025935"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:33:39.456954+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash

## Summary
- Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.
- Net loss $5.4M for Q2 includes $3.2M non-cash charges; cash $838K at June 30.
- Received CE Mark for LockeT product; European sales expected to start in Q3 2025.
- Completed acquisition of Cardionomic heart failure assets via 82%-owned subsidiary Cardionomix.
- Formed Kardionav JV for implant-based software to locate ventricular tachycardia ablation sites.

## SEC filing metadata
- accession: 0001437749-25-025935
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000143774925025935/0001437749-25-025935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000143774925025935/vtak20250811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-025935
- JSON: https://secwatch.observer/filing/0001437749-25-025935.json
- Plain text: https://secwatch.observer/filing/0001437749-25-025935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.